by admin | Jun 16, 2026 | Careers
COMPANY DESCRIPTION Exogenus Therapeutics is a biotechnology company dedicated to advancing innovative healthcare solutions based on extracellular vesicles (EV). Our lead asset, EXO-101, is expected to enter clinical trials in early 2028. Our team is passionate about...
by admin | Jan 12, 2026 | News
Exogenus Therapeutics is thrilled to announce the granting of a new patent in the United States, marking a major milestone in the company’s global expansion. This is the second region to recognize the patent family titled: “Compositions comprising small extracellular...
by admin | May 5, 2025 | News
We are pleased to announce that Exogenus Therapeutics has been granted another patent, now in Europe! This is the fifth region to recognize the patent family titled “Use of umbilical cord blood-derived exosomes for tissue repair.” This patent family has also been...
by admin | Mar 11, 2025 | News
Lonza to develop a GMP-compliant process for Exo-101 manufacturing from its Siena (IT) site Exo-101 has shown safety and efficacy in multiple pre-clinical trials, and is expected to reach patients in 2027 Basel, Switzerland and Cantanhede, Portugal, 11 March 2025 –...
by admin | Sep 11, 2024 | News
We are pleased to announce that ExogenusTherapeutics has been granted another patent in Japan! This is the second patent granted in this region, and the first one to be granted within the family entitled “Compositions comprising small extracellular vesicles...
